neurology Archives - Pharmaphorum

Merck tries again in Alzheimer’s with Teijin’s tau antibody

May 26, 2017

Target is implicated in a number of nervous system diseases.

Merck tries again in Alzheimer’s with Teijin’s tau antibody

https://pharmaphorum.com/news/merck-aims-alzheimers-breakthrough-teijins-tau-antibody/

Celgene MS pill can’t beat older rival on disability progression

May 24, 2017

Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.

Celgene MS pill can’t beat older rival on disability progression

https://pharmaphorum.com/news/celgenes-ms-pill/

Virtual reality stroke rehab platform gets FDA clearance

May 19, 2017

MindMotion Pro helps with upper-limb rehabilitation following a stroke.

Virtual reality stroke rehab platform gets FDA clearance

https://pharmaphorum.com/news/vr-stroke-rehab-fda-clearance/

Data keeps Lilly in race for new migraine treatment

May 16, 2017

Company still in race to develop CGRP inhibitor for migraine.

Data keeps Lilly in race for new migraine treatment

https://pharmaphorum.com/news/eli-lilly-still-race-cgrp-migraine-drug-galcanezumab/

Ionis hit by safety concerns, rivals Alnylam benefit

May 16, 2017

Biotech insists drug for rare inherited disorder is still approvable.

Ionis hit by safety concerns, rivals Alnylam benefit

https://pharmaphorum.com/news/ionis-inotersen-meets-efficacy-targets-fap-safety-concerns-spook-investors/

Kite shares sink after death in CAR-T trial

May 9, 2017

Investors spooked after cerebral oedema death.

Kite shares sink after death in CAR-T trial

https://pharmaphorum.com/news/kite-shares-sink-death-car-t-trial/

FDA approves first ALS treatment for two decades

May 8, 2017

FDA asked Mitsubishi to file Radicava following approval in Japan.

FDA approves first ALS treatment for two decades

https://pharmaphorum.com/news/fda/

Laquinimod failure is bad news for Teva’s MS hopes

May 8, 2017

Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a

Laquinimod failure is bad news for Teva’s MS hopes

https://pharmaphorum.com/news/teva-ends-rd-laquinimod-relapsing-ms/

Biotech IPO market heats up as BioHaven’s debut impresses

May 5, 2017

BioHaven raises $168 million with biggest biotech IPO seen this year.

Biotech IPO market heats up as BioHaven’s debut impresses

https://pharmaphorum.com/news/biotech-ipo-market-heats-biohaven-makes-debut/

Trending

neurology

Merck tries again in Alzheimer’s with Teijin’s tau antibody

Celgene MS pill can’t beat older rival on disability progression

Data keeps Lilly in race for new migraine treatment

Ionis hit by safety concerns, rivals Alnylam benefit

Kite shares sink after death in CAR-T trial

FDA approves first ALS treatment for two decades

Laquinimod failure is bad news for Teva’s MS hopes

Biotech IPO market heats up as BioHaven’s debut impresses

4th Life Science Knowledge Management Summit

4th Clinical Regulatory Medical Writing Forum

Joint 23rd Medicines for Europe – 20th IGBA Annual Conference

AZ highlights data from next-gen oncology drugs at ASCO

FDA’s Gottlieb reveals plans to tackle generic price abuses

Apple and Nokia settle, sign digital health deal

Merck tries again in Alzheimer’s with Teijin’s tau antibody

GW close to filing cannabis-based epilepsy drug

Digital health round-up: FDA digital unit on track

Just how much does the NHS spend on medicines?

Patient-led trials: a formula for success

Health literacy: help pharma communicate with patients

Dynamic consent models can benefit clinical trials

Search

Advanced Search

Trending

neurology